IRADIMED CORP reported second-quarter 2026 results with revenue of $20.47M, roughly flat year‑over‑year, while net income and diluted EPS declined to $5.22M and $0.41, respectively, reflecting margin pressure from new-product production.
Financial Highlights
- Revenue was $20.466M for Q2 2026, compared with $20.409M in Q2 2025; YoY change 0.3%.
- Net income was $5.218M for Q2 2026, compared with $5.774M in Q2 2025; YoY change (9.7%).
- Diluted EPS was $0.41 for Q2 2026, compared with $0.45 in Q2 2025; YoY change (8.9%).
Business Highlights
- Revenue growth was modest: Q2 revenue rose 0.5% YoY to $20.5M and was up 6% for the year‑to‑date to $42.4M, driven by device launches and disposables growth.
- Geographic mix shifted as U.S. sales declined 8% in Q2 while international sales increased 69%, moving the domestic mix to 82% from 89% a year earlier.
- Product momentum included launch and bookings of the MRidium® 3870 IV pump and strong demand for monitors, boosting device and consumable sales.
- Gross margin compressed to 74% from 78% due to initial production inefficiencies associated with new product manufacturing.
- Cash from operations increased and investing spend fell after completion of a facility expansion, supporting ongoing growth plans and capacity.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.